Comparative Pharmacology
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus PRANTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus PRANTAL.
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE vs PRANTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; homatropine methylbromide is an anticholinergic that reduces gastrointestinal motility and secretions.
Prantal (diphemanil methylsulfate) is a quaternary ammonium anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing gastrointestinal motility, gastric acid secretion, and bronchial secretions. It does not cross the blood-brain barrier.
1 tablet (containing homatropine methylbromide 5 mg and hydrocodone bitartrate 5 mg) orally every 4 to 6 hours as needed for cough. Maximum 6 tablets per 24 hours.
50-100 mg orally 3-4 times daily; maximum 600 mg/day
None Documented
None Documented
Hydrocodone: Terminal elimination half-life 3.8-6.4 hours (mean ~4.5 h) in adults; prolonged in hepatic/renal impairment (up to 12-15 h). Homatropine methylbromide: Terminal half-life ~4-6 hours via quaternary structure limiting CNS penetration.
Terminal elimination half-life is 4-6 hours; steady-state achieved within 24 hours in patients with normal renal function.
Hydrocodone: Renal excretion of metabolites (hydromorphone, norhydrocodone) as glucuronide conjugates (~60%) and unchanged drug (<10%). Biliary/fecal elimination accounts for ~20-30%. Homatropine methylbromide: Predominantly fecal elimination via biliary excretion as unchanged quaternary ammonium compound (~70-80%); renal excretion of unchanged drug (~10-20%).
Primarily renal (50-70% unchanged) with minor biliary excretion; fecal elimination accounts for approximately 10-20%.
Category D/X
Category C
Anticholinergic
Anticholinergic